- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Longeveron Appoints Than Powell as Chief Business Officer | 60 | GlobeNewswire (Europe) | Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology... ► Artikel lesen | |
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| Di | Longeveron schließt Patientenrekrutierung für pädiatrische Herzstudie zu HLHS ab | 1 | Investing.com Deutsch | ||
| Di | Longeveron completes enrollment in HLHS pediatric heart trial | 1 | Investing.com | ||
| Di | Longeveron Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS) | 43 | GlobeNewswire (Europe) | Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submission for full traditional approval... ► Artikel lesen | |
| 20.06. | Longeveron Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 16.06. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | Longeveron to Attend BIO International Convention 2025 | 7 | GlobeNewswire (USA) | ||
| 12.05. | Longeveron Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient | 3 | GlobeNewswire (USA) | ||
| 08.05. | Longeveron Q1 2025 slides: promising clinical data amid financial headwinds | 1 | Investing.com | ||
| 08.05. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Longeveron Announces First Quarter 2025 Financial Results and Provides Business Update | 102 | GlobeNewswire (Europe) | Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to... ► Artikel lesen | |
| 08.05. | Longeveron Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 28.03. | Longeveron files $70M mixed securities shelf | 1 | Seeking Alpha | ||
| 20.03. | Longeveron Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease | 234 | GlobeNewswire (Europe) | Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer's diseaseAlignment with FDA on proposed trial study design... ► Artikel lesen | |
| 14.03. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.03. | Longeveron Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B) in Alzheimer's Disease | 217 | GlobeNewswire (Europe) | Phase 2a results demonstrated laromestrocel (Lomecel-B) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's diseaseThis encouraging clinical trial data... ► Artikel lesen | |
| 03.03. | Longeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call Transcript | 1 | Insider Monkey | ||
| 28.02. | Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update | 333 | GlobeNewswire (Europe) | Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more... ► Artikel lesen | |
| 28.02. | Longeveron Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.02. | Longeveron Inc. - 10-K, Annual Report | - | SEC Filings |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| CUREVAC | 4,560 | -0,91 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 40,600 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline | -New Phase 1 clinical data for CTX310 continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86%... ► Artikel lesen | |
| OCUGEN | 0,858 | -1,06 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
| CYTODYN | 0,258 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer | VANCOUVER, Washington, June 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,046 | +8,27 % | SOL Global Investments Corp.: SOL Global Announces Board Changes and Strategic Focus on Crypto Innovation | Toronto, Ontario--(Newsfile Corp. - June 24, 2025) - SOL Global Investments Corp. (CSE: SOL) (FSE: 9SB) ("SOL Global" or the "Company"), one of the first publicly traded companies focused on institutional... ► Artikel lesen | |
| CELLECTIS | 1,220 | -1,13 % | Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025 | ||
| ANAVEX LIFE SCIENCES | 8,300 | +4,48 % | Anavex Life Sciences Corp. Q2 Loss Beats Estimates | WASHINGTON (dpa-AFX) - Anavex Life Sciences Corp. (AVXL) released Loss for second quarter that beat the Street estimates.The company's earnings came in at -$11.20 million, or -$0.13 per share.... ► Artikel lesen | |
| CERUS | 1,151 | +2,86 % | CERUS CORP - 8-K, Current Report | ||
| WINDTREE THERAPEUTICS | 0,450 | -1,43 % | Windtree Therapeutics: Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel | Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of... ► Artikel lesen | |
| APTEVO THERAPEUTICS | 2,841 | -0,59 % | Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules | SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based... ► Artikel lesen | |
| HARVARD BIOSCIENCE | 0,448 | +8,21 % | HARVARD BIOSCIENCE INC - 8-K, Current Report | ||
| ENTERA BIO | 1,662 | +1,59 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
| XBRANE BIOPHARMA | 0,012 | 0,00 % | Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia | Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane... ► Artikel lesen | |
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung |
Das Unternehmen LONGEVERON INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,325 Euro und damit +1,92 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.